[1] Edmond MB, Wallance SE, McClish DK, et al. Nosocomial bloodstream infections in United States hospitals:a three-year analysis[J]. Clin Infect Dis, 1999, 29(2):234.
[2] Li L, Ding H, Wang B, et al. Synthesis and evaluation of novel azoles as potent antifungal agents[J]. Bioorg Med Chem Lett, 2014, 24(1):192-194.
[3] Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stemcell transplant recipients[J]. Clin Infect Dis, 2002, 7:909-917.
[4] Ramirez E, Garcia-Rodriguez J, Borobia AM, et al. Use of antifungal agents in pediatric and adult high-risk areas[J]. Eur J Clin Microbiol Infect Dis, 2012, 3:337-347.
[5] Desai VC, Cavanaugh TM, Kelton CM, et al. Trends in the utilization of, spending on, and prices for outpatient antifungal agents in US Medicaid programs:1991-2009[J]. Clin Ther, 2012, 10:2118-2131.
[6] Jiang Z, Wang Y, Wang W, et al. Discovery of highly potent triazole antifungal derivatives by heterocycle-benzene bioisosteric replacement[J]. Eur J Med Chem, 2013, 64:16-22.
[7] Wang S, Jin G, Wang W, et al. Synthesis and structure-activity relationships of new triazole derivatives containing N-substituted phenoxpropylamino side chains[J]. Eur J Med Chem, 2012, 53(4):292-299.
[8] Richardson K. Antifungal 1,3-bis-triazolyl-2-propanol derivative:4404216[P]. USA, 1983-09-13.
[9] Zou Y, Yu S, Li R, et al. Synthesis, antifungal activities and molecular docking studies of novel 2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl dithiocarbamates[J]. Eur J Med Chem, 2014, 74:366-374.
[10] National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts approved standard[S]. Document M27-A2, Wayne, PA, 2002.